journal
MENU ▼
Read by QxMD icon Read
search

Leukemia Research Reports

journal
https://www.readbyqxmd.com/read/27812500/an-etv6-abl1-fusion-in-a-patient-with-chronic-myeloproliferative-neoplasm-initial-response-to-imatinib-followed-by-rapid-transformation-into-all
#1
Purvi M Kakadia, Ralf Schmidmaier, Andreas Völkl, Irene Schneider, Natalia Huk, Stephanie Schneider, Gerda Panzner, Ulrike Neidel, Barbara Fritz, Karsten Spiekermann, Stefan K Bohlander
We report the case of a 26 year-old patient presenting with a persistent leukocytosis and CML-like marrow but no evidence of a BCR/ABL1 fusion. Molecular cytogenetics revealed that a portion of the ETV6 locus was inserted into the ABL1 locus. An ETV6/ABL1 fusion transcript could subsequently be confirmed. The patient was started on imatinib and went into complete cytomorphological remission. QRT-PCR measurements showed a 4 log reduction of the ETV6/ABL1 fusion. 15 months later, the disease transformed into ALL and the patient expired...
2016: Leukemia Research Reports
https://www.readbyqxmd.com/read/27752467/novel-therapeutic-options-in-acute-myeloid-leukemia
#2
Michael Medinger, Claudia Lengerke, Jakob Passweg
Acute myeloid leukemia (AML) is a biologically complex and molecularly and clinically heterogeneous disease, and its incidence is increasing as the population ages. Cytogenetic anomalies and mutation testing remain important prognostic tools for tailoring treatment after induction therapy. Despite major advances in understanding the genetic landscape of AML and its impact on the pathophysiology and biology of the disease, as well as the rapid development of new drugs, standard treatment options have not experienced major changes during the past three decades...
2016: Leukemia Research Reports
https://www.readbyqxmd.com/read/27656412/involvement-of-cd147-on-multidrug-resistance-through-the-regulation-of-p-glycoprotein-expression-in-k562-adr-leukemic-cell-line
#3
Aoranit Somno, Songyot Anuchapreeda, Nuttapol Chruewkamlow, Supansa Pata, Watchara Kasinrerk, Sawitree Chiampanichayakul
The relationship between P-gp and CD147 in the regulation of MDR in leukemic cells has not been reported. This study aimed to investigate the correlation between CD147 and P-gp in the regulation of drug resistance in the K562/ADR leukemic cell line. The results showed that drug-resistant K562/ADR cells expressed significantly higher P-gp and CD147 levels than drug-free K562/ADR cells. To determine the regulatory effect of CD147 on P-gp expression, anti-CD147 antibody MEM-M6/6 significantly decreased P-gp and CD147 mRNA and protein levels...
2016: Leukemia Research Reports
https://www.readbyqxmd.com/read/27547725/congenital-b-lymphoblastic-leukemia-with-a-cryptic-mll-rearrangement-and-post-treatment-evolution-to-mixed-phenotype-acute-leukemia
#4
Elizabeth Moschiano, Gordana Raca, Cecilia Fu, Paul K Pattengale, Mathew J Oberley
Congenital leukemia is a rare event with a poor prognosis. We report a case of congenital leukemia with a cryptic rearrangement of MLL demonstrable only with RT-PCR. Interestingly, with treatment, the patient showed lineage plasticity of the leukemia with the development of monocytic lineage blasts after presenting with B-cell lineage blasts. This was heralded by the development of a new clonal cytogenetic abnormality. This case highlights the primitive nature of the leukemic cells in congenital leukemia, and emphasizes that RT-PCR for MLL rearrangements may identify a subset of cases which are otherwise negative by karyotyping, FISH, and chromosomal microarrays...
2016: Leukemia Research Reports
https://www.readbyqxmd.com/read/27489766/enhanced-international-prognostic-index-in-japanese-patients-with-diffuse-large-b-cell-lymphoma
#5
Aya Nakaya, Shinya Fujita, Atsushi Satake, Takahisa Nakanishi, Yoshiko Azuma, Yukie Tsubokura, Masaaki Hotta, Hideaki Yoshimura, Kazuyoshi Ishii, Tomoki Ito, Shosaku Nomura
To evaluate the National Comprehensive Cancer Network (NCCN) International Prognostic Index (IPI), we analyzed 284 patients treated with the combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in our institution in Japan. Their 5-year overall survival (OS) by risk level was 80.7%, 74.8%, 55.4% and 67.5% (P=0.005); and their 5-year progression-free survival (PFS) was 76.8%, 78.6%, 63.7% and 58.3% (P=0.0722). The NCCN-IPI is a simple scale that uses conventional clinical factors, but did not reflect survival in our cohort...
2016: Leukemia Research Reports
https://www.readbyqxmd.com/read/27489765/a-remarkable-hematological-and-molecular-response-pattern-in-a-patient-with-polycythemia-vera-during-combination-therapy-with-simvastatin-and-alendronate
#6
Anders Lindholm Sørensen, Klaus Kallenbach, Hans Carl Hasselbalch
We report a 57-year old man with polycythemia vera, who had a remarkable hematological and molecular response during treatment with simvastatin and alendronate. The patient was treated with this combination for 56 months, and during this period the patient has been in complete hematological remission. The JAK2-V617F allele burden has dropped from 64% to sustained values below 20%, and follow-up bone marrow biopsies have revealed no change in PV features, without any regular cytoreductive treatment.
2016: Leukemia Research Reports
https://www.readbyqxmd.com/read/27489764/changing-of-ikzf1-genotype-during-philadelphia-negative-precursor-b-acute-lymphoblastic-leukemia-progression-a-short-clinical-report
#7
Volha Vshyukova, Alexander Meleshko, Natalia Mihal, Olga Aleinikova
•The case demonstrated a rare event of clonal heterogeneity by IKZF1 gene status in BCRABL1- ALL.•IKZF1 deletions are secondary events in ALL caused by clonal evolution during the treatment.•It's prognostic significance could be more crucial in BCR-ABL- rather than in BCR-ABL + ALL.•IKZF1 gene alterations may be determined and proved at the genome, expression and protein level.•IKZF1 deletions are suitable for MRD detection but not stable compared to Ig/TCR rearrangement.
2016: Leukemia Research Reports
https://www.readbyqxmd.com/read/27453816/a-case-of-srsf2-mutation-in-chronic-lymphocytic-leukemia
#8
Eduardo Garza, Giovanni Del Poeta, Carmen Martínez-Losada, Gianfranco Catalano, Loredana Borgia, Maria Liliana Piredda, Emiliano Fabiani, Valter Gattei, Francesco Lo-Coco, Nélida I Noguera
Chronic lymphocytic leukemia (CLL) is characterized by extremely variable clinical course indicating substantial differences in the biology of the disease. Molecular characterization provides new insights useful for treatment decision making. We report on a patient diagnosed with CLL, whose disease was characterized by episodes of rapid progression and disease stabilization, and in which a SRSF2 gene mutation was identified in the absence of other commonly known mutations of CLL. To the best of our knowledge this is the first case of SRSF2 gene mutation ever reported in CLL...
2016: Leukemia Research Reports
https://www.readbyqxmd.com/read/27453815/chronic-lymphocytic-lymphoma-and-concomitant-renal-cell-carcinoma-clear-cell-type-review-of-the-literature
#9
Burak Uz, Ilhan Dolasik, Ozlem Ucer, Adile Ferda Dagli, Sercan Simsek
In the present report, a 73 years-old male patient who developed clear cell type renal cell carcinoma (RCC) 5 years after the diagnosis of chronic lymphocytic lymphoma (CLL) and plausible explanations for this association were discussed by the authors. The incidence of CLL and RCC occurring in the same patient is higher than that expected in the general population. Various explicative hypotheses of this concurrence include treatment-related development of a second malignancy, immunomodulatory mechanisms, viral aetiology, cytokine (interleukin 6) release from a tumor, and common genetic mutations...
2016: Leukemia Research Reports
https://www.readbyqxmd.com/read/27408788/acute-myeloid-leukemia-in-the-older-adults
#10
REVIEW
Antonio M Almeida, Fernando Ramos
AML is an aggressive hematological malignancy with highest incidence in the older adults. The adverse features of AML in the elderly, and the frailties and comorbidities frequently present in them, make their management a particularly difficult therapeutic challenge. In this context, it is important to assess carefully patient- as well as disease-associated prognostic features with validated tools. The fittest patients should be considered for curative therapy, such as bone marrow transplantation, whereas low intensity options may be more appropriate for frail patients...
2016: Leukemia Research Reports
https://www.readbyqxmd.com/read/27298759/genomic-imbalances-in-peripheral-blood-confirm-the-diagnosis-of-myelodysplastic-syndrome-in-a-patient-presenting-with-non-immune-hemolytic-anemia
#11
Mohammad Faizan Zahid, Nadia Khan, Jianming Pei, Joseph R Testa, Essel Dulaimi
Myelodysplastic syndrome (MDS) is a clonal stem-cell disorder characterized by dyshematopoiesis. We report a patient who presented with cytopenias and microangiopathic hemolytic anemia. Chromosome microarray analysis (CMA), using single nucleotide polymorphism arrays, on peripheral blood revealed genomic imbalances indicative of MDS, which was confirmed by bone marrow examination. This report highlights the importance of suspecting MDS in patients with cytopenias and microangiopathic hemolytic anemia. CMA of peripheral blood may assist in the preliminary diagnosis of MDS, representing a comparatively less invasive diagnostic procedure and may aid bone marrow evaluation when an aspirate sample is insufficient for conventional cytogenetic analysis...
2016: Leukemia Research Reports
https://www.readbyqxmd.com/read/27182486/erythroid-blast-crisis-in-chronic-myelogenous-leukemia-case-report-and-review-of-literature
#12
Rochelle Nagales Nagamos, Teresa Gentile, Neerja Vajpayee
Chronic myelogenous leukemia (CML) is a myeloproliferative disorder where over a period of time 15-20% of patients show blastic transformation with majority transforming into acute myeloid leukemia, most of which are of granulocytic lineage. Erythroid blast phase of CML is relatively rare with the incidence ranging from 0-10%. Further the incidence of acute erythroid leukemia by itself is fairly low amongst all acute leukemias. We report a case of 41-year-old patient with CML who failed to achieve cytogenetic remission, transformed to acute erythroid leukemia and eventually succumbed to the disease over a short period of time...
2016: Leukemia Research Reports
https://www.readbyqxmd.com/read/27144120/the-formation-of-an-aberrant-pax5-transcript-in-a-patient-with-mixed-phenotype-acute-leukemia-harboring-der-9-t-7-9-q11-2-p13
#13
Jun Amaki, Hiromichi Matsushita, Yuka Kitamura, Ryoko Nagao, Hiromichi Murayama, Minoru Kojima, Kiyoshi Ando
We experienced the case of a 56-year-old male with B-lymphoid/myeloid lineage mixed phenotype acute leukemia (MPAL). A cytogenetic analysis of the patient's bone marrow revealed a complex karyotype, including der(9)t(7;9)(q11.2;p13). We identified an aberrant PAX5 transcript, including the exons 1A to 5 and the contiguous intron 5/6 sequence using the 3' rapid amplification of cDNA ends-polymerase chain reaction method, and confirmed their expression in the leukemic cells. Our case suggests that der(9)t(7;9)(q11...
2016: Leukemia Research Reports
https://www.readbyqxmd.com/read/27144119/refractory-acute-promyelocytic-leukemia-successfully-treated-with-combination-therapy-of-arsenic-trioxide-and-tamibarotene-a-case-report
#14
Minoru Kojima, Daisuke Ogiya, Akifumi Ichiki, Ryujiro Hara, Jun Amaki, Hidetsugu Kawai, Hiroki Numata, Ai Sato, Mitsuki Miyamoto, Rikio Suzuki, Shinichiro Machida, Hiromichi Matsushita, Yoshiaki Ogawa, Hiroshi Kawada, Kiyoshi Ando
A 40-year-old male developed refractory acute promyelocytic leukemia (APL) after various treatments including all-trans retinoic acid, tamibarotene, arsenic trioxide (As2O3), conventional chemotherapy, and autologous peripheral blood stem cell transplantation. We attempted to use both tamibarotene and As2O3 as a combination therapy, and he achieved molecular complete remission. Grade 2 prolongation of the QTc interval on the electrocardiogram was observed during the therapy. The combination therapy of As2O3 and tamibarotene may be effective and tolerable for treating refractory APL cases who have no treatment options, even when they have previously been treated with tamibarotene and As2O3 as a single agent...
2016: Leukemia Research Reports
https://www.readbyqxmd.com/read/26904404/clonal-evolution-of-aml-on-novel-fms-like-tyrosine-kinase-3-flt3-inhibitor-therapy-with-evolving-actionable-targets
#15
Pashtoon M Kasi, Mark R Litzow, Mrinal M Patnaik, Shahrukh K Hashmi, Naseema Gangat
UNLABELLED: For acute myeloid leukemia (AML), identification of activating mutations in the FMS-like tyrosine kinase-3 (FLT3) has led to the development of several FLT3-inhibitors. Here we present clinical and next generation sequencing data at the time of progression of a patient on a novel FLT3-inhibitor clinical trial (ASP2215) to show that employing therapeutic interventions with these novel targeted therapies can lead to consequences secondary to selective pressure and clonal evolution of cancer...
2016: Leukemia Research Reports
https://www.readbyqxmd.com/read/26870659/four-hepatosplenic-t-cell-lymphoma-cases-of-japanese-patients
#16
Hidetsugu Kawai, Hiromichi Matsushita, Ken Ohmachi, Minoru Kojima, Shinichiro Machida, Yoshiaki Ogawa, Hiroshi Kawada, Naoya Nakamura, Kiyoshi Ando
Hepatosplenic T-cell lymphoma (HSTCL), a rare type of γδ T-cell lymphoma, is characterized by hepatosplenomegaly and cytopenias. It is associated with immunodeficiency and its age of onset is reportedly between the 20s and 30s. We herein report 4 Japanese HSTCL cases. Three of them, including an elderly case that was 74 years of age, were not at adolescence. No cases had a history of immunodeficiency. All other disease phenotypes were similar to the typical HSTCL cases. These findings suggest that there are a certain proportion of HSTCL patients who presented after middle age...
2016: Leukemia Research Reports
https://www.readbyqxmd.com/read/26870658/an-unexpected-and-devastating-adverse-event-of-dasatinib-rhabdomyolysis
#17
Burak Uz, Ilhan Dolasik
We, herein, describe a 52-year-old male whom developed rhabdomyolysis and acute renal failure likely related to dasatinib shortly after the administration of treatment. After withdrawal of dasatinib, the myalgia reduced, and his CK returned to normal levels within a week. On follow-up acute renal failure did resolve without requiring dialysis, but unfortunately the patient died of severe respiratory distress. We recommend that musculoskeletal symptoms should be monitorized during therapy with dasatinib, and CML patients with musculoskeletal symptoms should have CK levels checked in order to prevent this unexpected but devastating adverse event...
2016: Leukemia Research Reports
https://www.readbyqxmd.com/read/26716080/unusual-massive-bone-marrow-fibrosis-in-acute-promyelocytic-leukemia-following-arsenic-trioxide-therapy
#18
S Venkatesan, Abhishek Purohit, Ankur Ahuja, Dinesh Chandra, Mukul Aggarwal, R Amrita, Ravi Kumar, Manoranjan Mahapatra, Hara P Pati, Seema Tyagi
Bone marrow fibrosis has been associated with different types of non-neoplastic conditions like granulomatous and autoimmune diseases and a variety of neoplastic disorders such as acute megakaryoblastic leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma and myeloproliferative neoplsms. Therapy induced fibrosis is a rare phenomenon. Here we report a case of an incidentally diagnosed acute promyelocytic leukemia (APL) with t(11;17) which was treated with arsenic trioxide (ATO) for 45 days. However, the patient did not go into remission and developed massive fibrosis of bone marrow...
2015: Leukemia Research Reports
https://www.readbyqxmd.com/read/26716079/young-woman-with-mild-bone-marrow-dysplasia-gata2-and-asxl1-mutation-treated-with-allogeneic-hematopoietic-stem-cell-transplantation
#19
Anna Lübking, Sebastian Vosberg, Nikola P Konstandin, Annika Dufour, Alexander Graf, Stefan Krebs, Helmut Blum, Axel Weber, Stig Lenhoff, Mats Ehinger, Karsten Spiekermann, Philipp A Greif, Jörg Cammenga
Heterozygous mutations in GATA2 underlie different syndromes, previously described as monocytopenia and mycobacterial avium complex infection (MonoMAC); dendritic cell, monocytes, B- and NK lymphocytes deficiency (DCML); lymphedema, deafness and myelodysplasia (Emberger syndrome) and familiar myelodysplastic syndrome/acute myeloid leukemia (MDS / AML). Onset and severity of clinical symptoms vary and preceding cytopenias are not always present. We describe a case of symptomatic DCML deficiency and rather discrete bone marrow findings due to GATA2 mutation...
2015: Leukemia Research Reports
https://www.readbyqxmd.com/read/26716078/detection-of-a-pdgfrb-fusion-in-refractory-cmml-without-eosinophilia-a-case-for-broad-spectrum-tumor-profiling
#20
Gillian C Bell, Eric Padron
In this case report, we describe a refractory CMML case without eosinophilia harboring a PDGFRB rearrangement leading to a favorable response with imatinib. We believe this case demonstrates the utility of broad spectrum genomic profiling in refractory CMML cases as an opportunity to uncover additional treatment options.
2015: Leukemia Research Reports
journal
journal
47893
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"